Besnoline

Besnoline

Tolperisone

treatment of pathologically increased muscle tone and spasms of striated muscles resulting from organic diseases of the central nervous system (damage to the pyramidal pathways, multiple sclerosis, brain stroke, myelopathy, encephalomyelitis),

treatment of increased tone and muscle spasms, muscle contractures accompanying diseases of the organs of movement (including spondylosis, spondyloarthrosis, cervical and lumbar syndromes, arthrosis of large joints),

rehabilitation treatment after orthopedic and traumatological operations,

as part of the combination therapy of obliterating vascular diseases (obliterating atherosclerosis, diabetic angiopathy, obliterating thrombangiitis, Raynaud's disease, diffuse scleroderma), diseases arising from vascular innervation disorders (acrocyanosis, intermittent angioedema),

Little's disease (infantile brain paralysis) and other encephalopathies accompanied by muscular dystonia.

Inside, after eating, without chewing, with a small amount of water.

Adults and children from 14 years old - usually starting with 50 mg 2-3 times a day, gradually increasing the dose to 150 mg 2-3 times a day.

Children from 3 to 6 years old — Besnoline^® assign inside in a daily dose of 5 mg/kg, 7-14 years old - 2-4 mg / kg (in 3 doses during the day).

hypersensitivity to any of the components of the drug,

myasthenia gravis,

children under 3 years of age.

Muscle weakness, headache, hypotension, nausea, vomiting, abdominal discomfort. With a reduction in the dose, side effects usually disappear. In rare cases, allergic reactions occur (itching, erythema, urticaria, angioedema, anaphylactic shock, bronchospasm).

Data on the overdose of the drug Besnoline^® not received.

Treatment: gastric lavage and symptomatic therapy are recommended. There is no specific antidote.

Central-acting muscle relaxant. The mechanism of action is not fully understood. It has a membrane-stabilizing, local anesthetic effect, inhibits the conduction of impulses in primary afferent fibers and motor neurons, which leads to blocking of spinal mono - and polysynaptic reflexes. It also probably inhibits the release of mediators by inhibiting the intake of Ca for a second time.² to the synapses. In the brain stem, it eliminates the facilitation of arousal along the reticulospinal pathway. Increases peripheral blood flow regardless of the influence of the central nervous system. In the development of this effect plays the role of a weak spasmolytic and adrenoblokatorami effect tolperisone.

After oral administration, tolperizone is well absorbed from the gastrointestinal tract. C_max it is achieved after 0.5-1 h, the bioavailability is about 20%.

Tolperison metabolized in the liver and kidneys. It is excreted in the urine in the form of metabolites (more than 99%). The pharmacological activity of the metabolites is unknown.

• Central-acting muscle relaxant [n-Cholinolytics (muscle relaxants)]

Data on interactions that limit the use of the drug Besnoline^®, not available.

Although tolperizone has an effect on the central nervous system, it does not cause a sedative effect, so it can be used in combination with sedatives, hypnotics and drugs containing alcohol.

It does not affect the effect of alcohol on the central nervous system.

Tolperizone increases the effect of niflumic acid, with the simultaneous use of these drugs, it may be necessary to reduce the dose of niflumic acid.

Funds for General anesthesia, peripheral muscle relaxants, psychotropic drugs, clonidine — enhance the effect tolperisone.